HC Wainwright Reiterates $30.00 Price Target for Abeona Therapeutics (ABEO)

Abeona Therapeutics (NASDAQ:ABEO) has been assigned a $30.00 price objective by HC Wainwright in a report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 65.29% from the stock’s current price.

ABEO has been the subject of several other research reports. Maxim Group reissued a “buy” rating and set a $35.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, February 7th. Cantor Fitzgerald set a $36.00 price objective on Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 20th. ValuEngine raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Royal Bank of Canada reissued a “buy” rating and set a $26.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $28.88.

Shares of NASDAQ ABEO opened at $18.15 on Thursday. Abeona Therapeutics has a 12 month low of $4.55 and a 12 month high of $22.75. The stock has a market cap of $838.28, a PE ratio of -27.50 and a beta of 1.29.



Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Abeona Therapeutics had a negative return on equity of 24.57% and a negative net margin of 3,263.92%. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.24 million. Abeona Therapeutics’s revenue for the quarter was down 16.0% compared to the same quarter last year. research analysts forecast that Abeona Therapeutics will post -0.79 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas purchased a new stake in Abeona Therapeutics in the fourth quarter worth approximately $163,000. MetLife Investment Advisors LLC purchased a new stake in Abeona Therapeutics in the fourth quarter worth approximately $194,000. SG Americas Securities LLC purchased a new stake in Abeona Therapeutics in the fourth quarter worth approximately $218,000. Virtu Financial LLC purchased a new stake in Abeona Therapeutics in the fourth quarter worth approximately $246,000. Finally, Virtus Fund Advisers LLC purchased a new stake in Abeona Therapeutics in the fourth quarter worth approximately $346,000. 62.04% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://dakotafinancialnews.com/2018/04/12/hc-wainwright-reiterates-30-00-price-target-for-abeona-therapeutics-abeo.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply